Dr Rick Thompson joined Beacon (formerly known as Findacure) as the organisation’s third team member and its first-ever Scientific Officer, with a focus on developing the charity’s work in drug repurposing.
He became CEO in 2017 and has since played a key role in guiding Beacon’s strategy and supporting the delivery of its projects across the rare disease space.
Rick holds a PhD in evolutionary biology and previously studied moles at the University of Cambridge’s Museum of Zoology. He regularly contributes to the European rare disease community through talks, training, and written work, and is continually inspired by the dedication and insight of the patient group leaders that Beacon supports.
